6533b832fe1ef96bd129a4a1

RESEARCH PRODUCT

Care pathways for the selection of a biologic in severe asthma.

Ulrich WahnRoland BuhlAndrew Menzies GowAlvaro A. CruzWilliam W. BusseWanda PhipatanakulJean BousquetNicola A. HananiaChristian DomingoMarc HumbertRatko DjukanovicGuy BrusselleMichael E. Wechsler

subject

Pulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaMEDLINEmacromolecular substancesOmalizumab03 medical and health sciences0302 clinical medicineReslizumabmedicineHumans030212 general & internal medicineIntensive care medicineSelection (genetic algorithm)Randomized Controlled Trials as TopicAsthma therapyBiological Productsbusiness.industryAntibodies MonoclonalAsthma030228 respiratory systemPractice Guidelines as TopicCritical PathwaysbusinessMepolizumabmedicine.drug

description

Physicians need care pathways to select a biologic in type 2 severe asthma (omalizumab, mepolizumab, reslizumab) http://ow.ly/pygw30gB7Bv

yearjournalcountryeditionlanguage
2017-12-01The European respiratory journal
10.1183/13993003.01782-2017https://pubmed.ncbi.nlm.nih.gov/29217605